Author | Vanessa Caceres

Rheumatoid arthritis patients who have had a malignancy and are receiving a TNFi or rituximab (RTX), do not appear to have an increased risk of cancer recurrence.

Brief report in the journal Arthritis Care and Research shows that patients report favorable outcomes with a tofacitinib/DMARD combo therapy.

Some patients are not being screened or treated for glucocorticoid-induced osteoporosis by primary care physicians or rheumatologists.

Treg cells are more prevalent in patients with juvenile idiopathic arthritis and active inflammation, as compared to patients in remission.

Rheumatoid arthritis patients are inherently at higher risk of melanoma, but a new study shows that biologics do not increase that risk.

EULAR 2016: Patient education and compliance often take a back seat to disease management, but they need to be at the forefront of care.